
CSTL Stock Forecast & Price Target
CSTL Analyst Ratings
Bulls say
Castle Biosciences Inc. has demonstrated significant growth potential, as evidenced by a 92% year-over-year increase in TissueCypher test volume and a 23% quarter-over-quarter rise in 2Q25, likely bolstered by the expansion of the sales force. The company has also improved the gross margin of its TissueCypher product, with expectations of a mature gastrointestinal sales force by the second half of 2025, which could further enhance revenue generation. Comparatively, the slower growth of the DecisionDx-Melanoma test, at only 4% year-over-year, highlights TissueCypher's increasing prominence in the company's portfolio and its potential to drive future financial performance.
Bears say
Castle Biosciences Inc. faces a challenging outlook, as the expected enterprise value (EV) to revenue multiples for its dermatology and DecisionDx-UM tests are projected to be significantly lower than those for the TissueCypher product. This suggests that the market may not fully recognize the future revenue potential of the company's main offerings, particularly DecisionDx-Melanoma. Additionally, even when applying conservative estimates, the stock still appears undervalued, indicating potential concerns regarding investor confidence or broader market dynamics.
This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
CSTL Analyst Forecast & Price Prediction
Start investing in CSTL
Order type
Buy in
Order amount
Est. shares
0 shares